Pharmaceutical & Healthcare Research Report | Pipeline Analysis | Clinical Trials & Resutls

Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

noreply@blogger.com (Manish Baghel) — Tue, 09 Jul 2019 09:22:00 +0000

Post-Traumatic Stress Disorder (PTSD) is a serious condition that occurs in people who have experienced or witnessed a life-threatening event, such as a natural disaster, serious accident, terrorist incident, sudden death of a loved one, war, rape, or other violent personal assault. The fear due to such incidents triggers many split-second changes in the body, which protect the body in adverse situations.

Download free sample copy of report at: https://www.pharmaproff.com/request-sample/1238

PTSD is not diagnosed unless the symptoms last for at least one month. In order to be diagnosed with PTSD, a person must have three different types of symptoms: re-experiencing symptoms, avoidance and numbing symptoms, and arousal symptoms. Cognitive behavioral therapy (CBT) and family therapy are some of the therapies used to treat PTSD. ZOLOFT (by Pfizer Inc.), a selective serotonin reuptake inhibitor (SSRI), is being used for the treatment of PTSD.

According to the research findings, majority of the pipeline drug candidates are being developed to be administered by oral route. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for PTSD through oral route has shown promising results in clinical studies.
Companies that are involved in developing therapeutics for PTSD have shown positive clinical results in the various phases of drug development. For instance, BNC210, a negative allosteric modulator of the A7 nicotinic acetylcholine receptor, is being developed by Bionomics Limited to treat patients with PTSD. The results from the phase II trial of BNC210 showed that BNC210 was safe and well tolerable in patients with PTSD.

Get the detailed analysis at: https://www.pharmaproff.com/report/ptsd-therapeutics-pipeline-analysis

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co. Ltd. (Otsuka) entered into an agreement to develop and commercialize five innovative products in the field of psychiatry and neuroscience. In November 2018, Lundbeck and Otsuka reported positive phase II data from the combination treatment of brexpiprazole and sertraline for the treatment of PTSD.
Bionomics Limited, Pfizer Inc., India Globalization Capital Inc., Therapade Technologies LLC, Axim Biotechnologies Inc., H. Lundbeck A/S, and Otsuka Pharmaceutical Co. Ltd. are some of the major companies involved in the development of drug candidates for the treatment of PTSD.
The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of PTSD. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the PTSD therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to PTSD.

Vaginitis Therapeutics Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Tue, 25 Jun 2019 08:53:00 +0000

Vaginitis refers to the inflammation of vagina. It affects women of all ages but is most common during the reproductive years. Vaginitis occurs due to change in the balance of the yeast and bacteria that normally live in the vagina.

Download the sample report @ https://www.pharmaproff.com/request-sample/1151

This causes the lining of the vagina to become inflamed. Use of antibiotics, changes in hormone levels due to pregnancy, breastfeeding, menopause, douching, spermicides, sexual intercourse and infection can change the normal balance of the vagina.

Get the detailed analysis @ https://www.pharmaproff.com/report/vaginitis-therapeutics-pipeline-analysis

The main symptom of vaginitis is increased discharge with a strong fishy odour. Itching is not common, but may be present if there is a lot of discharge. Vaginitis can be diagnosed by taking a sample of the discharge from vagina, which is then observed under a microscope. The treatment depends on the cause of the vaginitis. It may include a pill or a cream or gel that is applied to the vagina.

The drug candidates in vaginitis pipeline include, but are not limited to, Polygynax and Tamoxifen vaginal. Some of the companies in vaginitis therapeutics pipeline are Lumavita AG and Fulhold Pharma Limited.

Androgenetic Alopecia Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years

noreply@blogger.com (Manish Baghel) — Fri, 21 Jun 2019 12:34:00 +0000

Androgenetic alopecia is a genetic disorder of patterned hair loss that affects both men and women. The disorder shortens hair growth cycle due to excess of androgen, which eventually delays hair growth. Some of the major symptoms include gradual recession of frontal hairline, increased hair fall, bitemporal recession of hair, and thinning of the hair. The symptoms start appearing at the age of 20 and are seen to be prominent in people aged 40 years and above. The disorder leads to hair thinning near crown region, and maybe caused due to various genetic as well as environmental factors. The disorder can also occur due to hormonal imbalance, improper functioning of androgen hormones, poor diet, and excessive smoking.

Download the sample report at: https://www.pharmaproff.com/request-sample/1234

Androgenetic alopecia can diagnose with the help of blood tests, thyroid tests, biopsy, transferrin iron-binding capacity, Norwood Hamilton Scale assessment in men, and dehydroepiandrosterone sulfate (DHEAS) and testosterone analysis in women. The disorder can be treated by surgical transplantation, medical procedures, and low-level light therapy.
Propecia is one of the key U.S. Food and Drug Administration (USFDA) approved drugs, developed by Merck & Co. Inc., for the treatment of androgenetic alopecia in men.

Browse Detailed Report at: https://www.pharmaproff.com/report/androgenic-alopecia-therapeutics-pipeline-analysis

According to the research, many drugs being developed for androgenetic alopecia, which are administered topically. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

There are several companies which have shown positive results of clinical trials. For instance, in February 2019, Cassiopea SpA announced effective result of Phase II clinical trial of Breezula for treatment of androgeneticalopecia.

It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of androgenetic alopecia therapeutics. These technologies play an important role in the drug development by helping the companies to develop more specific and effective targeted therapies. For instance, RepliCel Life Sciences is using its proprietary cell therapy technology to develop therapeutic candidates for pattern baldness and other disorders. It utilizes dermal sheath cup cells, which induce the growth of cells in the area of baldness.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1234

Samumed LLC, Brickell Biotech Inc., Aclaris Therapeutics Inc., Cassiopea S.p.A, Kerastem Technologies LLC, Almirall S.A., and RepliCel Life Sciences are the major players involved in the development of drug candidates for the treatment of androgenetic alopecia.

Interstitial Lung Disease Therapeutics Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Tue, 18 Jun 2019 09:32:00 +0000

Interstitial lung disease is a type of inflammatory disease that affects and thickens the interstitium of the lungs.

Download the sample report @ https://www.pharmaproff.com/request-sample/1126

The interstitium is a lace like network of the tissue that provide support to the air sacs and the capillaries in the interstitium which allows the gas exchange between the blood and alveolar tissues.

Some of the types of the condition include interstitial pneumonia, idiopathic pulmonary fibrosis, and non-specific interstitial pneumonitis. Major symptoms associated with the disease include dry cough and shortness of breath.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1126

Regend Therapeutics is in the process of developing lung stem cells as a cell therapy for the treatment of interstitial lung disease. Boehringer Ingelheim GmbH is in the process of developing nintedanib as a fibroblast growth factor receptor antagonist for the treatment of this medical condition.

Akt/Protein Kinase B (PKB) Inhibitors to Witness Significant Growth due to Positive Clinical Results in the Coming Years

noreply@blogger.com (Manish Baghel) — Wed, 12 Jun 2019 11:22:00 +0000

According to a new research report “Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff Akt/PKB inhibitors therapeutics currently exhibits a proliferating pipeline with 23 therapeutic candidates.

Download the sample report @ https://www.pharmaproff.com/request-sample/1154

Akt plays a critical role in the regulation of cell’s apoptotic pathway and it is being studied extensively for targeting cancerous cells. Akt inhibitors are therapeutics that obstruct the Akt pathways or Akt enzyme, which play a key role in proliferation of solid tumors or cancer cells. Akt are composed of various AGC kinases present in the cells that have hydrophobic motif at the c-terminus of their catalytic core.

Get the detailed analysis @ https://www.pharmaproff.com/report/pkb-inhibitors-pipeline-analysis

The companies who are developing Akt/PKB inhibitors for the treatment of various chronic diseases have shown positive clinical results in the various phases of drug development. For instance, in June 2018, F. Hoffman-La Roche Ltd. announced the interim results of Phase II study (LOTUS) for the drug candidate, ipatasertib, that showed improvement in patients with triple negative breast cancer (TNBC) toward overall survival (OS). This result was presented in the 2018 ASCO Annual Meeting, held in the U.S. The Phase II LOTUS study showed an increase in OS up to 23.1 months (median) in interventional study, as compared to 18.4 months (median) in placebo study.

Some of the key players involved in the development of Akt/PKB inhibitors include F. Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech Co. Ltd.

Turner Syndrome Therapeutics Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Fri, 07 Jun 2019 12:49:00 +0000

Turner syndrome is a chromosomal condition, which occurs when one of the two X chromosomes normally found in women is missing or incomplete. The disease alters the growth and development in females. The symptoms can vary among women who have Turner syndrome.

Women with this condition tend to be shorter than average and are usually unable to conceive a child because of an absence of ovarian function. Some other features of this condition are extra skin on the neck (webbed neck), heart defects and kidney problems, puffiness or swelling (lymphedema) of the hands and feet, and skeletal abnormalities.

Want to more info about Turner Syndrome Therapeutics pipeline analysis Download the research study at: https://www.pharmaproff.com/request-sample/1149

This condition occurs in about one in 2,500 female births worldwide, but is much more common among pregnancies that do not survive to term (miscarriages and stillbirths).

The drug candidates of Turner syndrome disease pipeline include, but are not limited to are Estradiol and Somatropin pegylated. Some of the companies having drugs in the Turner syndrome disease pipeline are Novo Nordisk A/S, GeneScience Pharmaceuticals Co. Ltd., and Polus Inc.

Pipeline of Uveal Melanoma Therapeutics

noreply@blogger.com (Manish Baghel) — Mon, 03 Jun 2019 13:15:00 +0000

Uveal Melanoma Therapeutics Pipeline Analysis Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body. The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia.

The management of uveal melanoma can be divided into globe-preserving therapy or enucleation. Globe-preserving therapies can broadly classified into radiation, surgical, and laser therapy.

Download the sample report @ https://www.pharmaproff.com/request-sample/1121

The drug candidates of uveal melanoma disease pipeline include, but not limited to, nivolumab and IMCgp100. Some of the companies having drugs in the uveal melanoma therapeutics pipeline includes Harmonic Pharma, Immunocore Ltd. and Celldex Therapeutics, Inc.

Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Clinical Trials & Results

noreply@blogger.com (Manish Baghel) — Fri, 31 May 2019 08:47:00 +0000

Mitogen-activated protein kinase (MAPK) are ubiquitous regulators of many cellular functions including cell proliferation, cellular growth, inflammatory responses to stress signals and cell differentiation. MAPK pathway, involves three main kinases, Raf, MEK and ERK, has emerged as a novel target for the development of new cancer therapies with reduced side-effects.

MAPK inhibitors are being developed as small molecules, for the treatment of various types of cancer. They have also showed additional benefits with high effectiveness at lower concentrations in comparison to the ATP-competitive inhibitors, for the cancer therapy.

Mereo BioPharma Group plc is in the process of developing Acumapimod as an oral p38 MAPK inhibitor for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). eFFECTOR Therapeutics Inc., Genentech Inc., and Kura Oncology Inc. are some other companies having pipeline of MAPK inhibitors.

Get the Pipeline Analysis of Mitogen-Activated Protein Kinase Inhibitors Therapeutics At: https://www.pharmaproff.com/request-sample/1206

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Clinical Trials & Results on Adrenocortical Carcinoma Therapeutics

noreply@blogger.com (Manish Baghel) — Tue, 28 May 2019 11:38:00 +0000

Adrenocortical carcinoma, also known as adrenal cortex carcinoma, is a rare form of cancer that occurs at the cortex layer of the adrenal gland. There are two adrenal glands present in the human body: one at the top of each kidney.

Each adrenal gland is comprised of two distinct structures: the outer part of the adrenal glands (adrenal cortex) and the inner region (adrenal medulla). Some of the genetic condition that can cause adrenocortical carcinoma are Li-Fraumeni syndrome, Carney complex, and Beckwith-Wiedemann syndrome.

Some of the most common symptoms of this medical condition includes abdominal pain, lump in the abdomen, and feeling of fullness. The disease can be diagnosed by imaging technique such as computed tomography (CT) scan, magnetic resonance imaging (MRI), biopsy, blood tests, and urine tests. Millendo Therapeutics Inc. is in the process of developing ATR-101 as an acetyl CoA C-acetyltransferase inhibitor for the treatment of adrenocortical carcinoma.

Download the Research Report About Adrenocortical Carcinoma Therapeutics Pipeline Analysis At: https://www.pharmaproff.com/request-sample/1109

Merck & Co., Inc. is also in the process of developing pembrolizumab as a CD274 antigen inhibitor for the treatment of adrenocortical carcinoma. Some of the other companies and universities having the pipeline drug for adrenocortical carcinoma includes the Columbia University, Medunik Canada Inc., HRA Pharma, and others.

Thymic Carcinoma Therapeutics Pipeline Analysis

noreply@blogger.com (Manish Baghel) — Wed, 22 May 2019 12:41:00 +0000

Thymic carcinoma, also known as thymomas, is a rare type of cancer that forms in the cells present in the outside surface of the thymus. Thymus is a small organ that lies in the upper chest under the breastbone. It is a part of the lymph system and produces certain types of white blood cells that helps the body to fight against infections.

The tumor cells in a thymoma look like the normal cells of the thymus which grow slowly and rarely spread beyond the thymus.

For more information about Thymic Carcinoma Therapeutics Clinical Trials & Results Download the Research report at: https://www.pharmaproff.com/request-sample/1119

The drug candidates of thymic carcinoma disease pipeline include, but not limited to, pembrolizumab, and milciclib maleate. Some of the companies having drugs in the thymic carcinoma disease pipeline includes Merck & Co. Inc., NMS Group SpA and Tiziana Life Sciences plc.

Sezary Syndrome Therapeutics Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Fri, 17 May 2019 12:13:00 +0000

Sezary syndrome, a type of cutaneous T-cell lymphoma, affects Sézary cells present in the skin, lymph nodes and blood. It accounts approximately 3 to 5 percent of cases of cutaneous T-cell lymphoma.

Sézary syndrome is more prevalent in males compared to females. It is characterized by red, severely itchy rash that covers large areas of the body. The common symptoms of Sézary syndrome includes alopecia, lymphadenopathy, palmoplantar keratoderma, ectropion and abnormalities of the fingernails and toenails.

The standard treatments for Sézary syndrome are combination of phototherapy and chemotherapy, and medications including vorinostat and romidepsin. Takeda Pharmaceutical Company Limited is in the process of developing brentuximab vedotin for the treatment of Sézary syndrome.

For more information about Sezary Syndrome Therapeutics Pipeline download the research study at: https://www.pharmaproff.com/request-sample/1118

Bone Metastases Therapeutics- Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Thu, 16 May 2019 13:22:00 +0000

Bone metastases is a common form of cancer of the skeleton that inhabits in bone marrow and stimulates the local bone activity.

In this condition, the normal bone homeostasis disrupts which leads to the development of the tumour. Some of the major symptoms observed in patients with bone metastases are bone pain, spinal cord compression, and high blood calcium levels.

Bone metastases can be diagnosed by various types of imaging tests such as X-Ray, bone scan, positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) scan, blood tests, urine tests, and bone biopsy. ChemoCentryx, Inc. is in the process of developing CCX354 as a CCR1 receptor antagonist for the treatment of bone metastases. Moreover, Amgen Inc. is developing denosumab as a RANKL ligand inhibitor for the treatment of this medical condition. Pfizer Inc., and Eli Lilly and Company are also key players having drugs for bone metastases in their pipeline.

For more information about Bone Metastases Therapeutics Pipeline Get the sample report at:
https://www.pharmaproff.com/request-sample/1112

Vitamin Analogues Therapeutics-Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Fri, 10 May 2019 10:04:00 +0000

Vitamins are nutrients that are required for the growth of the body. Based on its solubility, vitamins are categorized into two types: fat soluble vitamins, and water-soluble vitamins. Vitamins have a variety of function in the body, such as vitamin A improves eye sight, vitamin D is essential for bone growth and has hormone like function that regulates mineral metabolism.

The largest group of vitamins is vitamin B complex, which is essential for activation of enzymes. Vitamin H, also known as biotin, is involved in the regulation of fatty acids. Several vitamin analogues, such as vitamin D, vitamin A, and vitamin B1 analogues are being developed for the treatment of vitamin related disorders.

Vitamin D analogues are under clinical studies as being beneficial for bone growth and metabolism and also experiments are going on animal models of cancer in Pre-Clinical studies. Vitamin B1 analogues are helpful in treating vitamin B1 related disease, such as beri-beri and Wernicke’s encephalopathy.

Aphios Corporation is developing APH-0701 as a non-toxic Vitamin D3 analogue for the treatment of hormone refractory prostate cancer. Some of the companies with vitamin analogues in their pipeline are Xeragenx LLC. and Deltanoid Pharmaceuticals Inc. among others.

For more information about Vitamin Analogues Therapeutics Pipeline Analysis request for sample report at : https://www.pharmaproff.com/request-sample/1193

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Gorlin Syndrome Therapeutics- Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Wed, 08 May 2019 12:30:00 +0000

Gorlin syndrome, also known as basal cell nevus syndrome, is an inherited genetic disorder characterized by multiple basal cell skin cancer.

The common symptoms observed during Gorlin syndrome are calcium deposition in brain, jaw cysts, skeletal changes and developmental disability. The person with Gorlin syndrome appears with a prominent forehead, widely spaced eyes, small skin bumps and skin cysts.

Want to know more about Gorlin Syndrome Therapeutics Pipeline request to get the sample report at: https://www.pharmaproff.com/request-sample/1113

Gorlin syndrome is screened by neurological evaluation, dental X-Ray and measurement of head size. The main treatment for Gorlin syndrome includes imiquimod cream, chemotherapy, photodynamic therapy and retinoids.

Ascend Biopharmaceuticals Ltd. is in the process of developing ASN-002, a chemoimmunotherapy, for the treatment of Gorlin syndrome. PellePharm Inc., and F. Hoffmann-La Roche Ltd. are some other key players having drugs for Gorlin syndrome in their pipeline.

p53 Antigen Modulators Therapeutics Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Tue, 07 May 2019 12:44:00 +0000

p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis.

Thus, new opportunities in cancer immunotherapy are expected to develop better drug candidates targeting p53, with complete understanding of interactions between p53 and the immune system, to avoid various adverse events.

The major challenge is prevention of tissue damage by selectively modulating p53 activity, under pathophysiological conditions that generate redox stress.

p53 antigen modulator therapies are being widely studied for the development of various target specific cancer therapies. Dendritic cell-derived vaccines, adenoviral p53 vectors, MDM2 inhibitors and small-molecules to reinstate the DNA binding activity of p53 are some commercial approaches as p53 antigen modulator therapies, for the treatment of various indications. Also, research studies have demonstrated that novel therapeutic strategies are being developed to overcome the challenges related to in-depth knowledge of p53 and associated pathways.

Quark Pharmaceuticals Inc. is developing QPI-1002 as a nuclease-resistant, synthetic double-stranded RNA oligonucleotide designed to temporarily inhibit the expression of the pro-apoptotic gene p53, for the treatment of delayed graft function and acute kidney injury. Some of the companies having a therapeutic pipeline of p53 antigen modulators include Innovation Pharmaceuticals Inc., Aprea Therapeutics, and Actavalon Inc.

For more information about p53 Antigen Modulators Therapeutics Pipeline Analysis request to get a sample report at: https://www.pharmaproff.com/request-sample/1195

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Wnt Signaling Pathway Inhibitors to Witness Significant Growth due to Positive Clinical Results in the Coming Years

noreply@blogger.com (Manish Baghel) — Mon, 06 May 2019 12:56:00 +0000

Wnt signaling pathway plays an important role in embryonic development. The signaling pathway regulates cell-to-cell interaction, accelerates trophoblast development, activates blastocyst, accelerate chorion-allantois fusion and implantation. A wide range of diseases, such as different types of cancer and degenerative diseases can be treated by deregulation of components involved in Wnt/β-catenin signaling pathway. Also, researchers have demonstrated that moderate weakening of Wnt signaling can eliminate its carcinogenic potential. Based on the recent researches, Wnt Signaling Pathway inhibitors have also shown potential in cardiovascular disorders.

Get a sample report at: https://www.pharmaproff.com/request-sample/1210

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; and has less risk of systemic infections. Administration of Wnt Signaling Pathway Inhibitors through oral route has shown promising results in the clinical studies. Also, according to the analysis, maximum number of drugs in the pipeline are being developed as small molecules.

The companies developing Wnt Signaling Pathway inhibitors for the treatment of cancer and degenerative diseases, have shown positive clinical results in the various phases of drug development. For instance, in October 2018, Samumed LLC, announced the topline data from the phase IIb trial SM04690 in knee osteoarthritis, wherein the treatment with SM04690 showed improvement in function, pain, and global scores of patients.

Some of the key players involved in the development of Wnt signaling pathway inhibitors in the late and mid stage include Samumed LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics Inc., Leap Therapeutics Inc., 2X Oncology Inc., Eisai Co. Ltd., and Novartis AG.

Acquired Immunodeficiency Syndrome (AIDS) Related Cancer Therapeutics- Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Thu, 02 May 2019 12:35:00 +0000

Acquired immunodeficiency syndrome (AIDS) related cancer include those types of cancer which occurs in patients suffering from AIDS.

People with AIDS are reported to be highly suspected to the occurrence of lymphomas. According to the American Society of Clinical Oncology, Kaposi sarcoma is very common in patients with AIDS; whereas non-Hodgkin’s lymphoma is second most common in patients with AIDS.

Women with AIDS are at high risk for developing cervical intraepithelial neoplasia. The National Cancer Institute is in the process of developing chemotherapy and HAART; and EPOCH-rituximab, for the treatment of AIDS related lymphoma.

For more info visit: https://www.pharmaproff.com/report/aids-related-cancer-therapeutics-pipeline-analysis

Sufentanil - API Insight, 2018

noreply@blogger.com (Manish Baghel) — Mon, 29 Apr 2019 12:32:00 +0000

Sufentanil, sold under the brand names of Dsuvia and Sufenta, is basically a synthetic opioid analgesic drug, which is used for the medication of acute pain relief. It helps to offer properties of sedation and this makes it a good analgesic component of anesthetic regimen during a surgical process.

Download the sample report at: https://www.pharmaproff.com/request-sample/1167

It has greater potency than morphine and Fentanyl, often used in surgery and post-operative pain management for patients that are heavily opioid dependent or tolerant because of long term opiate use for chronic pain or illicit opiate use. In the present market, Sufentanil has proven to be the strongest opioid painkiller available.

In 2018, the Food and Drug Association had approved Dsuvia, a sublingual tablet form of the drug, that was developed in a collaboration between AcelRx Pharmaceuticals Inc. and the United States Department of Defense for use in battlefield settings where intravenous treatments may not be available. Some of the side-effects include heart rhythm irregularity, blood pressure changes and nausea/vomiting.

This report provides details of the drug and the API manufacturers across the 7 major markets which includes U.S, EU5, and Japan. It includes the overview, mechanism, regulatory milestones, strategic developments, the historical and forecasted sales. The pipeline analysis of the drug by phase which would include the product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

Telangiectasias Therapeutics- Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Fri, 26 Apr 2019 13:13:00 +0000

Telangiectasias are dilated blood vessels located near the surface of skin or mucous membranes. These often appear as fine pink or red lines, which temporarily whiten under pressure. Although this disease can be developed in healthy individuals, telangiectasias is known to be a prime feature of systemic and limited scleroderma and dermatomyositis.

Telangiectasias may occur in rosacea, in certain systemic diseases (such as ataxia-telangiectasia, scleroderma), or in long-term therapy with topical fluorinated corticosteroids.

For more information get the sample report at:
https://www.pharmaproff.com/report/telangiectasis-therapeutics-pipeline-analysis

Spider telangiectases, costal fringe, generalised essential telangiectasia, hereditary haemorrhagic telangiectasia, angioma serpiginosum, unilateral naevoid telangiectasia and poikilodermatous mycoses fungoides are some types of primary telangiectases. Although most telangiectases are self-limiting, for cosmetically sensitive areas of the body, gentle cautery can be used for small numbers of lesions.

Pontine Glioma Therapeutics- Pipeline Analysis 2018

noreply@blogger.com (Manish Baghel) — Tue, 23 Apr 2019 13:06:00 +0000

Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM).

Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.

Request to get the sample report at: https://www.pharmaproff.com/request-sample/1117

The only efficient treatment for pontine glioma is radiotherapy; as surgery is not possible due to the tumor’s position in the brain stem. Company like Y-mAbs Therapeutics Inc. is in the process of developing omburtamab for the treatment of pontine glioma.